These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7907218)

  • 1. Two cases of long term dopamine D2 receptor blockade after depot neuroleptics.
    Harasko-van der Meer C; Brücke T; Wenger S; Fischer P; Deecke L; Podreka I
    J Neural Transm Gen Sect; 1993; 94(3):217-21. PubMed ID: 7907218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects.
    Schlösser R; Schlegel S; Hiemke C; Nickel O; Bockisch A; Rao ML; Hahn K
    Psychiatry Res; 1997 Sep; 75(2):103-14. PubMed ID: 9351492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.
    Farde L; Nordström AL; Wiesel FA; Pauli S; Halldin C; Sedvall G
    Arch Gen Psychiatry; 1992 Jul; 49(7):538-44. PubMed ID: 1352677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.
    Liu PY; Wu PC; Chen CY; Chen YC
    Gen Hosp Psychiatry; 2011; 33(1):84.e5-7. PubMed ID: 21353143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 8. Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia.
    Johnson DA
    Br J Hosp Med; 1977 Jun; 17(6):546-58. PubMed ID: 18242
    [No Abstract]   [Full Text] [Related]  

  • 9. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
    Knable MB; Heinz A; Raedler T; Weinberger DR
    Psychiatry Res; 1997 Sep; 75(2):91-101. PubMed ID: 9351491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depot fluphenazine decanoate and enanthate for schizophrenia.
    David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late-Onset Rhabdomyolysis Associated With an Intramuscular Injection of Fluphenazine Decanoate.
    Umino M; Kobayashi R; Nisijima K; Suda S
    Prim Care Companion CNS Disord; 2017 Sep; 19(5):. PubMed ID: 28972705
    [No Abstract]   [Full Text] [Related]  

  • 12. Dopamine D2 receptor imaging and neuroleptic drug response.
    Heinz A; Knable MB; Weinberger DR
    J Clin Psychiatry; 1996; 57 Suppl 11():84-8; discussion 89-93. PubMed ID: 8941175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects.
    Broich K; Grünwald F; Kasper S; Klemm E; Biersack HJ; Möller HJ
    Pharmacopsychiatry; 1998 Sep; 31(5):159-62. PubMed ID: 9832346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A depot neuroleptic withdrawal study neurological effects.
    Wistedt B; Wiles D; Jørgensen A
    Psychopharmacology (Berl); 1983; 80(2):101-5. PubMed ID: 6136059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
    Nyberg S; Farde L; Halldin C
    Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diminution of hand writing area and D2-dopamine receptor blockade. Results from treatment with typical and atypical neuroleptics].
    Künstler U; Hohdorf K; Regenthal R; Seese A; Gertz HJ
    Nervenarzt; 2000 May; 71(5):373-9. PubMed ID: 10846712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depot neuroleptics: side effects and safety.
    Marder SR
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of the use of fluphenazine in a depot preparation].
    Marcjan K; Pietruszewska I; Wolak E
    Psychiatr Neurol Med Psychol Beih; 1975; 20-21():176-82. PubMed ID: 829619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
    Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
    Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with depot neuroleptics in ambulatory practice.
    Fiolet J
    Acta Psychiatr Belg; 1981; 81(2):182-8. PubMed ID: 6117188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.